The therapeutic potential of Vx765 was illustrated not only by its inhibition of IL‐1β releases from human monocytes in vitro, but also by its effect in reducing the serum levels of IL‐1β and other clinical biomarkers in murine models of dermatitis, arthritis,11 and temporal lobe epilepsy.12 This evidence concerns the gene IL1B and skin disorder.